{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:53:45Z","timestamp":1777859625127,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacy Practice"],"published-print":{"date-parts":[[2011,10]]},"abstract":"<jats:p>Asenapine is a new psychopharmacologic agent approved for the acute and maintenance treatment of schizophrenia and the acute and maintenance treatment of manic and mixed episodes associated with bipolar I disorder. The efficacy of asenapine in treating schizophrenia was evaluated in four 6-week studies in which placebo and active controls (risperidone, olanzapine, and haloperidol) were used. Two 3-week placebo-controlled trials examined the efficacy of asenapine and active control (olanzapine) in the treatment of bipolar I disorder. Asenapine demonstrated efficacy in relation to placebo for 2 of the acute schizophrenia trials and both trials examining the acute treatment of bipolar I disorder. Several factors should be examined when considering asenapine therapy in relation to other antipsychotics including efficacy, atypicality of receptor binding, obstacles to administration and compliance, and finally cost. No efficacy advantage is evident with asenapine over other antipsychotic agents. Barriers to achieving compliance with asenapine include the recommendations of twice daily dosing, the need to avoid food and liquids for at least 10 minutes postadministration, the need for patient cooperation with sublingual administration, and the low bioavailability of the tablet if swallowed. Finally, no cost advantage is evident for using asenapine in comparison to the already available generic risperidone or other soon-to-be generic atypical antipsychotics.<\/jats:p>","DOI":"10.1177\/0897190011422875","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T15:10:09Z","timestamp":1323702609000},"page":"447-451","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Asenapine"],"prefix":"10.1177","volume":"24","author":[{"given":"Jessica M.","family":"Henry","sequence":"first","affiliation":[{"name":"Louis Stokes Cleveland Veteran Affairs Medical Center, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Fuller","sequence":"additional","affiliation":[{"name":"Louis Stokes Cleveland Veteran Affairs Medical Center, Cleveland, OH, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2011,12,12]]},"reference":[{"key":"bibr1-0897190011422875","unstructured":"Schering-Plough Corporation. Saphris (Asenapine) Sublingual Tablets US Prescribing Information. Revised August, 2009. http:\/\/www.spfiles.com\/pisaphrisv1.pdf. Accessed August 2010."},{"key":"bibr2-0897190011422875","doi-asserted-by":"publisher","DOI":"10.1177\/0269881107082944"},{"key":"bibr3-0897190011422875","unstructured":"United States Food and Drug Administration. Saphris (Asenapine) Sublingual Tablets. Briefing Book. 30 July 2009. http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM173877.pdf. Accessed August 2010."},{"key":"bibr4-0897190011422875","volume-title":"Drug Information Handbook for Psychiatry","author":"Fuller MA","year":"2009"},{"key":"bibr5-0897190011422875","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v68n1004"},{"key":"bibr6-0897190011422875","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181d35d6b"},{"key":"bibr7-0897190011422875","doi-asserted-by":"publisher","DOI":"10.1016\/j.jad.2009.12.028"},{"key":"bibr8-0897190011422875","doi-asserted-by":"publisher","DOI":"10.1111\/j.1399-5618.2009.00748.x"},{"key":"bibr9-0897190011422875","doi-asserted-by":"publisher","DOI":"10.1517\/14656560903061309"},{"key":"bibr10-0897190011422875","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(00)00911-5"},{"issue":"12","key":"bibr11-0897190011422875","first-page":"13","volume":"7","author":"Ventimiglia J","year":"2010","journal-title":"Psychiatry (Edgmont)"}],"container-title":["Journal of Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190011422875","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/0897190011422875","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/0897190011422875","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:34:35Z","timestamp":1777509275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/0897190011422875"}},"subtitle":["A New Antipsychotic Option"],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":11,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["10.1177\/0897190011422875"],"URL":"https:\/\/doi.org\/10.1177\/0897190011422875","relation":{},"ISSN":["0897-1900","1531-1937"],"issn-type":[{"value":"0897-1900","type":"print"},{"value":"1531-1937","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}